- The FDA approves UCB's (OTCPK:UCBJF) Cimzia (certolizumab pegol) for the treatment of non-radiographic axial spondyloarthritis, a type of inflammatory arthritis commonly associated with lower back pain (non-radiographic means that there are symptoms but no visible damage on X-rays). This is the first approved medication in the U.S. for the indication.
- The FDA initially approved the tumor necrosis factor inhibitor in April 2008 for Crohn's disease. It was subsequently approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis.